milrinone has been researched along with Injury, Myocardial Reperfusion in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (mPTP)." | 7.78 | Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. ( Cho, S; Hara, T; Higashijima, U; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S, 2012) |
| "There is little information regarding the comparative hemodynamic effects of adding milrinone or levosimendan to dopamine infusion in hypoxia-reoxygenated (H-R) newborns." | 7.78 | Milrinone is preferred to levosimendan for mesenteric perfusion in hypoxia-reoxygenated newborn piglets treated with dopamine. ( Bigam, DL; Cheung, PY; Churchill, T; Joynt, C; Manouchehri, N; Vento, M, 2012) |
| "The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients." | 6.79 | Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction. ( Chan, KH; Chan, MY; Fujise, K; Huang, MH; Lee, CH; Low, AF; Lui, CY; Nguyen, V; Poh, KK; Sia, W; Tan, HC; Tang, LQ; Tay, EL; Xu, X, 2014) |
| "Levosimendan has a more beneficial profile than milrinone regarding the development of ventricular arrhythmias during and after regional myocardial ischemia." | 5.33 | Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. ( Papp, JG; Pollesello, P; Varró, AF; Végh, AS, 2006) |
| "The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (mPTP)." | 3.78 | Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. ( Cho, S; Hara, T; Higashijima, U; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S, 2012) |
| "There is little information regarding the comparative hemodynamic effects of adding milrinone or levosimendan to dopamine infusion in hypoxia-reoxygenated (H-R) newborns." | 3.78 | Milrinone is preferred to levosimendan for mesenteric perfusion in hypoxia-reoxygenated newborn piglets treated with dopamine. ( Bigam, DL; Cheung, PY; Churchill, T; Joynt, C; Manouchehri, N; Vento, M, 2012) |
| "The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients." | 2.79 | Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction. ( Chan, KH; Chan, MY; Fujise, K; Huang, MH; Lee, CH; Low, AF; Lui, CY; Nguyen, V; Poh, KK; Sia, W; Tan, HC; Tang, LQ; Tay, EL; Xu, X, 2014) |
| "Levosimendan has a more beneficial profile than milrinone regarding the development of ventricular arrhythmias during and after regional myocardial ischemia." | 1.33 | Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. ( Papp, JG; Pollesello, P; Varró, AF; Végh, AS, 2006) |
| " To determine the role of beta adrenergic stimulation before ischemia, a dose-response study was undertaken with isoprotelenol and milrinone at 37 degrees C." | 1.30 | Is the use of catecholamine before ischemic arrest safe? Effect of catecholamine on rat heart ischemia/reperfusion injury. ( Newling, R; Shimada, Y; Yamamoto, F; Yamamoto, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ak, E | 1 |
| Ak, K | 1 |
| Ustandag, UV | 1 |
| Kervancioglu-Demirci, E | 1 |
| Emekli-Alturfan, E | 1 |
| Çetinel, S | 1 |
| Torregroza, C | 1 |
| Maas, K | 1 |
| Feige, K | 1 |
| Raupach, A | 2 |
| Stroethoff, M | 1 |
| Heinen, A | 2 |
| Hollmann, MW | 2 |
| Huhn, R | 2 |
| Behmenburg, F | 1 |
| Trefz, L | 1 |
| Dorsch, M | 1 |
| Ströthoff, M | 1 |
| Mathes, A | 1 |
| Berger, MM | 1 |
| Steppan, J | 1 |
| Berkowitz, DE | 1 |
| Nyhan, D | 1 |
| Poh, KK | 2 |
| Xu, X | 1 |
| Chan, MY | 1 |
| Lee, CH | 1 |
| Tay, EL | 1 |
| Low, AF | 1 |
| Chan, KH | 1 |
| Sia, W | 1 |
| Tang, LQ | 1 |
| Tan, HC | 2 |
| Lui, CY | 1 |
| Nguyen, V | 2 |
| Fujise, K | 2 |
| Huang, MH | 2 |
| Axelsson, B | 1 |
| Häggmark, S | 1 |
| Svenmarker, S | 1 |
| Johansson, G | 1 |
| Gupta, A | 1 |
| Tydén, H | 1 |
| Wouters, P | 1 |
| Haney, M | 1 |
| Usta, E | 1 |
| Mustafi, M | 1 |
| Scheule, AM | 1 |
| Ziemer, G | 1 |
| Wu, Y | 1 |
| Rastogi, S | 1 |
| McConnell, BK | 1 |
| Wijaya, C | 1 |
| Uretsky, BF | 1 |
| Matsumoto, S | 1 |
| Cho, S | 2 |
| Tosaka, S | 1 |
| Higashijima, U | 1 |
| Maekawa, T | 2 |
| Hara, T | 2 |
| Sumikawa, K | 2 |
| Manouchehri, N | 1 |
| Bigam, DL | 1 |
| Churchill, T | 1 |
| Joynt, C | 1 |
| Vento, M | 1 |
| Cheung, PY | 1 |
| Shibata, I | 1 |
| Yoshitomi, O | 1 |
| Ureshino, H | 1 |
| Papp, JG | 1 |
| Pollesello, P | 1 |
| Varró, AF | 1 |
| Végh, AS | 1 |
| Shimada, Y | 1 |
| Yamamoto, F | 2 |
| Yamamoto, H | 2 |
| Newling, R | 1 |
| Rechtman, MP | 1 |
| Van der Zypp, A | 1 |
| Majewski, H | 1 |
| Löwe, H | 1 |
| Jacobsohn, E | 1 |
| Komai, H | 1 |
| Tanaka, K | 1 |
| Ichikawa, H | 1 |
| Shibata, T | 1 |
| Koide, A | 1 |
| Ohashi, T | 1 |
| Nakashima, N | 1 |
| Kawashima, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction[NCT02098629] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-05-31 | Withdrawn (stopped due to Difficulty in enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for milrinone and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction.
Topics: Blood Pressure; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Infusions, Intra | 2014 |
15 other studies available for milrinone and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Milrinone Attenuates Heart and Lung Remote Injury after Abdominal Aortic Cross-Clamping.
Topics: Animals; Antioxidants; Aorta, Abdominal; Caveolin 1; Caveolin 3; Constriction; Disease Models, Anima | 2020 |
Combination of the Phosphodiesterase Inhibitors Sildenafil and Milrinone Induces Cardioprotection With Various Conditioning Strategies.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemody | 2020 |
Milrinone-Induced Postconditioning Requires Activation of Mitochondrial Ca
Topics: Animals; Cardiotonic Agents; Dose-Response Relationship, Drug; Large-Conductance Calcium-Activated P | 2018 |
Ischemic Postconditioning and Milrinone.
Topics: Animals; Disease Models, Animal; Ischemic Postconditioning; Milrinone; Myocardial Reperfusion Injury | 2018 |
Effects of Combined Milrinone and Levosimendan Treatment on Systolic and Diastolic Function During Postischemic Myocardial Dysfunction in a Porcine Model.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Drug Therapy, Combination; Hydrazones | 2016 |
Suppressing apoptosis with milrinone simulating extracorporeal circulation: a pilot study.
Topics: Aged; Apoptosis; Biopsy; Caspase 3; Cyclic Nucleotide Phosphodiesterases, Type 3; Extracorporeal Cir | 2010 |
Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Apoptosis; Cardiotonic Agents; Cyclic AMP-Dependent | 2011 |
Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts.
Topics: Animals; Blood Glucose; Disease Models, Animal; Hemodynamics; Hydrazones; Hyperglycemia; Male; Milri | 2012 |
Milrinone is preferred to levosimendan for mesenteric perfusion in hypoxia-reoxygenated newborn piglets treated with dopamine.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Dopamine; Drug Therapy, Combination; Hemodynamics; Hy | 2012 |
Milrinone and levosimendan administered after reperfusion improve myocardial stunning in swine.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Drug Administration Schedule; Female; Hemodynam | 2013 |
Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Coronary Vessels; Dogs; Electrophysiology; Female | 2006 |
Is the use of catecholamine before ischemic arrest safe? Effect of catecholamine on rat heart ischemia/reperfusion injury.
Topics: Adrenergic beta-Agonists; Animals; Dopamine; Epinephrine; In Vitro Techniques; Isoproterenol; Male; | 1999 |
Amrinone reduces ischaemia-reperfusion injury in rat heart.
Topics: 1-Methyl-3-isobutylxanthine; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifl | 2000 |
Protection of the hypoxic myocardium by the bispyridine derivatives AWD 122-14 and milrinone: studies on isolated, working right rabbit hearts.
Topics: Animals; Heart Rate; In Vitro Techniques; Milrinone; Morpholines; Myocardial Contraction; Myocardial | 1992 |
Harmful effects of inotropic agents on myocardial protection.
Topics: Animals; Body Temperature; Bucladesine; Calcium; Cardiotonic Agents; Creatine Kinase; Diltiazem; Hem | 1991 |